UroGen Pharma Ltd. (URGN:NASDAQ) closed at $36.61 on October 15, 2026, up 0.08% on the day. The stock trades 27.9% below its 52-week high of $50.81 and 123.7% above its 52-week low of $16.37. Over the past year, it gained 116.2%. UroGen Pharma Ltd. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -4.36% | -15.82% | -10.97% | +46.91% | +116.24% |
In 252 trading sessions since October 15, 2025, URGN closed higher on 126 days (50%). Its best day was November 6, 2025 (+21.91%) and its worst was December 2, 2025 (-14.34%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies.
Find more stocks like URGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.